Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms

Among the complications of diabetes, cardiovascular events and cardiac insufficiency are considered two of the most important causes of death. Experimental and clinical evidence supports the effectiveness of SGLT2i for improving cardiac dysfunction. SGLT2i treatment benefits metabolism, microcircula...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Keming, Luo, Xianling, Liao, Bin, Li, Guang, Feng, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103501/
https://www.ncbi.nlm.nih.gov/pubmed/37055837
http://dx.doi.org/10.1186/s12933-023-01816-5
_version_ 1785025864710225920
author Huang, Keming
Luo, Xianling
Liao, Bin
Li, Guang
Feng, Jian
author_facet Huang, Keming
Luo, Xianling
Liao, Bin
Li, Guang
Feng, Jian
author_sort Huang, Keming
collection PubMed
description Among the complications of diabetes, cardiovascular events and cardiac insufficiency are considered two of the most important causes of death. Experimental and clinical evidence supports the effectiveness of SGLT2i for improving cardiac dysfunction. SGLT2i treatment benefits metabolism, microcirculation, mitochondrial function, fibrosis, oxidative stress, endoplasmic reticulum stress, programmed cell death, autophagy, and the intestinal flora, which are involved in diabetic cardiomyopathy. This review summarizes the current knowledge of the mechanisms of SGLT2i for the treatment of diabetic cardiomyopathy. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10103501
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101035012023-04-15 Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms Huang, Keming Luo, Xianling Liao, Bin Li, Guang Feng, Jian Cardiovasc Diabetol Review Among the complications of diabetes, cardiovascular events and cardiac insufficiency are considered two of the most important causes of death. Experimental and clinical evidence supports the effectiveness of SGLT2i for improving cardiac dysfunction. SGLT2i treatment benefits metabolism, microcirculation, mitochondrial function, fibrosis, oxidative stress, endoplasmic reticulum stress, programmed cell death, autophagy, and the intestinal flora, which are involved in diabetic cardiomyopathy. This review summarizes the current knowledge of the mechanisms of SGLT2i for the treatment of diabetic cardiomyopathy. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2023-04-13 /pmc/articles/PMC10103501/ /pubmed/37055837 http://dx.doi.org/10.1186/s12933-023-01816-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Huang, Keming
Luo, Xianling
Liao, Bin
Li, Guang
Feng, Jian
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
title Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
title_full Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
title_fullStr Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
title_full_unstemmed Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
title_short Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
title_sort insights into sglt2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103501/
https://www.ncbi.nlm.nih.gov/pubmed/37055837
http://dx.doi.org/10.1186/s12933-023-01816-5
work_keys_str_mv AT huangkeming insightsintosglt2inhibitortreatmentofdiabeticcardiomyopathyfocusonthemechanisms
AT luoxianling insightsintosglt2inhibitortreatmentofdiabeticcardiomyopathyfocusonthemechanisms
AT liaobin insightsintosglt2inhibitortreatmentofdiabeticcardiomyopathyfocusonthemechanisms
AT liguang insightsintosglt2inhibitortreatmentofdiabeticcardiomyopathyfocusonthemechanisms
AT fengjian insightsintosglt2inhibitortreatmentofdiabeticcardiomyopathyfocusonthemechanisms

Ejemplares similares